Effects of FTY720 on peripheral blood lymphocytes and graft infiltrating cells in a rat model of chronic renal allograft rejection

Transplant Immunology
Martina KochBjoern Nashan

Abstract

Chronic renal allograft loss is still an unsolved problem in kidney transplantation. We evaluated the impact of FTY720, a S1P receptor agonist, known to deplete lymphocytes from the peripheral blood by sequestering them into lymph nodes and Peyer's patches, on blood lymphocytes and graft infiltrating cells in a rat model of chronic real allograft rejection. LEW rats served as recipients for LEW.1U7B kidney grafts. All animals were treated with CsA (5mg/kg) for 10 days after renal transplantation and monitored for kidney function, peripheral blood lymphocytes and graft infiltrating cells. In the intervention group (n=7) FTY720 therapy was started 7 weeks post-KTx in a dose of 0.5 mg/kg p. o. three times a week. In the control group the survival of the rats was 9, 11, 18 and 4 × 24 weeks, in the intervention group 2 × 8, 9, 2 × 11, 18 and 20 weeks. While in the intervention group the number of T- and B-lymphocytes in the peripheral blood was successfully reduced during FTY720 treatment, both groups showed significant amounts of T- and B-lymphocytes in the kidney grafts. Animals in both groups developed donor specific antibodies, extensive albuminuria and severe chronic changes in the grafts. FTY720 was highly effective to reduce ...Continue Reading

References

Aug 29, 1998·Clinical Biochemistry·P Troncoso, B D Kahan
Jun 20, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Klemens BuddeHans-Hellmut Neumayer
Jan 6, 2004·International Journal of Clinical Pharmacology and Therapeutics·T BöhlerK Budde
Jun 16, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Volker BrinkmannTimothy Hla
Jul 13, 2005·Transplant International : Official Journal of the European Society for Organ Transplantation·Corinna DoegeBjoern Nashan
Mar 14, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·K SolezJ J Weening
Nov 7, 2007·Transplantation·Helio Tedesco-SilvaUNKNOWN FTY720 2218 Clinical Study Group
Dec 25, 2007·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Banu SisKim Solez
Sep 14, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Andries J HoitsmaUNKNOWN FTY720 Phase II Transplant Study Group
Jul 29, 2015·Clinical and Experimental Pharmacology & Physiology·D GoltzR Meyer

❮ Previous
Next ❯

Citations

Mar 16, 2017·The Journal of Investigative Dermatology·Fen ShiBing Tang
Apr 15, 2020·American Journal of Respiratory Cell and Molecular Biology·Carole-Ann HuppéDavid Marsolais
Dec 31, 2020·Journal of the American Society of Nephrology : JASN·Yelena DrexlerSandra Merscher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.